Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model

Fig. 5

T7-EA induces a high quality immune response in an HBV mouse model. a The experimental procedure for the HBV therapeutic vaccine study. b Groups of HBV mice (n = 6 per group) were immunized intraperitoneally with HBV therapeutic vaccine consisting of T7-EA, Alum adjuvant and a recombinant HBsAg protein at day 0, 14 and 28. Normal saline and a traditional HBV vaccine were used as controls. HBsAg-specific IgG levels in the serum were measured by ELISA at the indicated time points. c HBV mice were sacrificed at day 132 and splenocytes were isolated; then, HBsAg-specific T cells were detected by Elispot assay. The cells were cultured at a density of 3 × 105 cells/well with 20 μg/mL HBsAg in a 96-well pre-coated Elispot plate for 18 h. SFC in 1 × 106 cells are shown. d HBsAg-specific T-cell positive rates. SFC were detected with Elispot and the cells cultured without HBsAg stimulation were used as a negative control. SFC in experimental wells with two times more than the negative control wells were regarded as being HBsAg-specific T-cell positive. SFC, spot-forming cells

Back to article page